Submit efficacy data of Indian population: CDSCO Panel Tells Eli Lilly for approval of additional indications of Ixekizumab Dr. Divya Colin9 Oct 2024 6:00 PM ISTNew Delhi: Citing that there is no efficacy data in the Indian population, the Subject Expert Committee (SEC) functional under the Central Drug...
Ixekizumab significantly relieves back pain, morning stiffness and disease activity in psoriatic arthritis Aditi22 Sept 2023 9:00 AM ISTPsoriatic arthritis (PsA) is a chronic inflammatory condition predominantly affecting peripheral joints. The disease has heterogeneous manifestations,...
Ixekizumab safe to use in Pediatric Patients with Moderate to Severe Plaque Psoriasis: JAMA Medical Dialogues Editorial Team30 April 2022 9:00 AM ISTA new study conducted by Amy S. Paller and team showed improvements in patient-reported outcomes and objective measures of full psoriasis skin...
Head-to-head trials reveal higher skin and nail clearance with ixekizumab in psoriasis patients Medha Baranwal15 April 2022 9:00 AM ISTUSA: In five head-to-head trials, treatment with ixekizumab in psoriasis patients was associated with higher rates of simultaneous complete skin and...
Continued ixekizumab therapy better than ixekizumab withdrawal in Psoriatic Arthritis patients MD Bureau2 Feb 2022 9:00 AM ISTThere are several disease-modifying antirheumatic drugs (DMARDs) available to patients with psoriatic arthritis (PsA), including conventional...
First case of Granuloma annulare after ixekizumab administration reported Dr Manoj Kumar Nayak10 Dec 2021 9:00 AM ISTGranuloma annulare post ixekizumab administration- 1 case report Psoriasis is a complex immune mediated disease influenced by multiple genetic...
